The expanding indications for clozapine

Experimental and Clinical Psychopharmacology

Volumn 5, Issue 3, 1997, Pages 216-234

  Young, Carl R ^b   Longhurst, James G ^b   Bowers Jr , Malcolm B ^b   Mazure, Carolyn M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PERPHENAZINE; TRANQUILIZER; VALPROIC ACID;

AGRANULOCYTOSIS; ARTICLE; BEHAVIOR DISORDER; DRUG INDICATION; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MENTAL DISEASE; ORTHOSTATIC HYPOTENSION; PSYCHOSIS; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; MOOD DISORDERS; NERVOUS SYSTEM DISEASES; SCHIZOPHRENIA;

EID: 0030806371     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.5.3.216     Document Type: Article

References (230)

1. Ackenheil, M., Beckmann, H., Greil, W., Hoffmann, G., Markianos, E., & Raese, J. (1974). Antipsychotic efficacy of clozapine in correlation to changes in catecholamine metabolism in man. Advances in Biochemistry and Psychopharmacology, 9, 647-657.
2. Ivir, J. M., & Lieberman, J. A. (1994). A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States experience. Journal of Clinical Psychopharmacology, 14, 87-89.
3. American Psychiatric Association. (1987). Diagnostic and statistical manual of mental disorders (3rd ed., rev.). Washington, DC: Author.
4. Arevalo, G. J., & Gershanick, O. S. (1993). Modulatory effect of clozapine on levodopa response in Parkinson's Disease: A preliminary study. Movement Disorders, 8, 349-354.
5. Asarnow, J. R., Tompson, M. C., & Goldstein, M. J. (1994). Childhood-onset schizophrenia: A follow-up study. Schizophrenia Bulletin, 20, 599-617.
6. Baker, R. W., Chengappa, K. N. R., Baird, J. W., Steingard, S., Christ, A. G., & Schooler, N. R. (1992). Emergence of obsessive-compulsive symptoms during treatment with clozapine. Journal of Clinical Psychiatry, 53, 439-442.
7. Baldessarini, R. J., & Frankenburg, F. R. (1991). Clozapine: A novel antipsychotic agent. New England Journal of Medicine, 324, 746-754.
8. Baldessarini, R. J., Huston-Lyons, D., Campbell, A., Marsh, E., & Cohen, B. M. (1992a). Clozapine attenuates NMDA receptor complex-mediated responses in vivo. Neuropsychopharmacology, 30, 557-565.
9. Baldessarini, R. J., Huston-Lyons, D., Campbell, A., Marsh, E., & Cohen, B. M. (1992b). Do central anti-adrenergic actions contribute to the atypical properties of clozapine? British Journal of Psychiatry, 160 (Suppl. 17), 12-16.
10. Baldessarini, R. J., Kando, J. C., & Centorrino, F. (1995). Hospital use of antipsychotic agents in 1989 and 1993: Stable dosing with decreased length of stay. American Journal of Psychiatry, 152, 1038-1044.
11. Banov, M. D., Zarate, C. A., Tohen, M., Scialabba, D., Wines, J. D., Kolbrener, M., Kim, J. W., & Cole, J. O. (1994). Clozapine therapy in refractory affective disorders: Polarity predicts response in long-term follow-up. Journal of Clinical Psychiatry, 55, 295-300.
12. Barnas, C., Zwierzina, H., Hummer, M., Sperner-Unterweger, B., Stern, A., & Fleischhacker, W. W. (1992). Granulocytemacrophage colony-stimulating factor (GM-CSF) treatment of clozapine-induced agranulocytosis: A case report. Journal of Clinical Psychiatry, 53, 245-247.
13. Bartko, G., Frecska, E., Horvath, S., Zador, G., & Arato, M. (1990). Predicting neuroleptic response from a combination of multilevel variables in acute schizophrenic patients. Acta Psychiatria Scandinavica, 82, 408-412.
14. Battegay, R., Cotar, B., Fleischenhauer, J., & Rauchfleisch, U. (1977). Results and side effects of treatment with clozapine (Leponex R). Comprehensive Psychiatry, 18, 423-428.
15. Bauer, M. S., Calabrese, J., Dunner, D. L., Post, R., Whybrow, P. C., Gyulai, L., Tay, L. K., Younkin, S. R., Bynum, D., & Lavori, P. (1994). Multisite data reanalysis of the validity of rapid cycling as a course modifier for Bipolar Disorder in DSM-IV. American Journal of Psychiatry, 151, 506-515.
16. Bebbington, P. E. (1995). The content and context of compliance. International Clinical Psychopharmacology, 9 (Suppl. 5), 41-50.
17. Bennett, J. P., Landow, E. R., Dietrich, S., & Schuh, L. A. (1994). Suppression of dyskinesias in advanced Parkinson's Disease: Moderate daily clozapine doses provide long-term dyskinesia reduction. Movement Disorders, 9, 409-414.
18. Bennett, J. P., Landow, E. R., & Schuh, L. A. (1993). Suppression of dyskinesias in advanced Parkinson's Disease II: Increasing daily clozapine doses suppress dyskinesias and improve parkinsonian symptoms. Neurology, 43, 1551-1555.
19. 3 and DAG: Two interacting second messengers. Annual Review of Biochemistry, 56, 159-193.
20. Blake, L. M., Marks, R. C., Nierman, P., & Luchins, D. J. (1991). Clozapine and clonzepam in tardive dystonia. Journal of Clinical Psychopharmacology, 11, 268-269.
21. Bonucelli, U., Ceravallo, R., Maremmani, C., Nuti, A., Rossi, G., & Muratorio, A. (1994). Clozapine in Huntington's chorea. Neurology, 44, 821-823.
22. Bowers, M. B., Jr., Mazure, C. M., Nelson, J. C., & Jatlow, P. I. (1990). Psychotogenic drug use and neuroleptic response. Schizophrenia Bulletin, 16, 81-86.
23. Brady, K., Anton, R., Ballenger, J. C., Lydiard, R. B., Adinoff, B., & Selander, J. (1990). Cocaine abuse among schizophrenic patients. American Journal of Psychiatry, 147, 1164-1167.
24. Breese, G. R., Baumeister, A. A., McCown, T. J., Emerick, S. G., Frye, G. D., Crotty, K., & Mueller, R. A. (1984). Behavioral differences between neonatal and 6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. Journal of Pharmacology and Experimental Therapeutics, 231, 334.
25. Breier, A. (1996). Mechanism of action of clozapine. Journal of Clinical Psychiatry Monograph, 14, 6-7.
26. Brown, G. L., & Linnoila, M. K. (1990). CSF serotonin metabolite (5-HIAA) studies in depression, impulsivity, and violence. Journal of Clinical Psychiatry, 51, 31-41.
27. Buck, J. A., & Sprague, R. C. (1989). Psychotropic medications in community long-term facilities. American Journal of Mental Retardation, 93, 618-623.
28. Buckley, P. F., Sajatovic, M., & Meltzer, H. Y. (1994). Treatment of delusional disorder with clozapine. American Journal of Psychiatry, 151, 1394-1395.
29. Buckley, P. F., Thompson, P., Way, L., & Meltzer, H. Y. (1994). Substance abuse among patients with treatment-resistant schizophrenia: Characteristics and implications for clozapine therapy. American Journal of Psychiatry, 151, 385-389.
30. Burke, R. E., Fahn, S., Jankovic, J., Marsden, C. D., Lang, A. E., Gollomp, S., & Illson, J. (1982). Tardive dystonia. Neurology, 32, 1335-1346.
31. Burkhardt, C., Kelly, J. P., Lim, Y. H., Filley, C. M., & Parker, W. D. (1993). Neuroleptic medications inhibit complex I of the electron transport chain. Annals of Neurology, 33, 512-517.
32. Burrell, M. F., Fewster, C., Szabadi, E., & Cashman, M. (1991). Clozapine-treated NMS. British Journal of Psychiatry, 158, 577.
33. Bustillo, J. R., & Buchanan, R. W. (1995). Neuroleptic-induced emesis: A new indication for clozapine. Biological Psychiatry, 38, 194-195.
34. Caine, E. D., Polinsky, R. J., Kartzinel, R., & Ebert, M. H. (1979). The trial use of clozapine for abnormal involuntary movement disorders. American Journal of Psychiatry, 136, 317-320.
35. Calabrese, J. R., Kimmel, S. E., Woyshville, M. J., & Meltzer, H. Y. (1993). Clozapine in mania [Abstract]. Proceedings of the 32nd annual meeting of the American College of Neuropsychopharmacology, p. 69. Honolulu, HI.
36. Calabrese, J. R., Kimmel, S. E., Woyshville, M. J., Rapport, D. J., Faust, C. J., Thompson, P. A., & Meltzer, H. Y. (1996). Clozapine for treatment-refractory mania. American Journal of Psychiatry, 153, 759-764.
37. Calabrese, J. R., Meltzer, H. Y., & Markovitz, P. J. (1991). Clozapine prophylaxis in rapid cycling bipolar disorder. Journal of Clinical Psychopharmacology, 11, 396-397.
38. Calabrese, J. R., & Woyshville, M. J. (1995). A medication algorithm for treatment of bipolar rapid cycling. Journal of Clinical Psychiatry, 56 (Suppl. 3), 11-18.
39. Campbell, M. (1985). Schizophrenic disorders and pervasive developmental disorders/infantile autism. In J. M. Weiner (Ed.), Diagnosis and psychopharmacology of childhood and adolescent disorders (pp. 114-150). New York: Wiley.
40. Campbell, M., Greg, D. M., Green, W. H., & Bennet, W. G. (1983). Neuroleptic-induced dyskinesias in children. Clinical Neuropharmacology, 6, 207-222.
41. Campbell, M., & Spencer, E. (1988). Psychopharmacology in child and adolescent psychiatry: A review of the past five years. Journal of the American Academy of Child and Adolescent Psychiatry, 27, 269-279.
42. Caroff, S. N., & Mann, S. C. (1993). Neuroleptic malignant syndrome. Contemporary Clinical Neurology, 77, 185-202.
43. Carpenter, W. T., Conley, R. R., Buchanan, R. W., Breier, A., & Tamminga, C. A. (1995). Patient response and resource management: Another view of clozapine treatment of schizophrenia. American Journal of Psychiatry, 152, 827-832.
44. Casey, D. E. (1989). Clozapine: Neuroleptic-induced EPS and tardive dyskinesia. Psychopharmacology, 99, S47-S53.
45. Chacko, R. C., Hurley, R. A., & Jankovic, J. (1993). Clozapine use in diffuse Lewy body disease. Journal of Neuropsychiatry and Clinical Neuroscience, 5, 206-208.
46. Chengappa, K. N. R., Shelton, M. D., Baker, R. W., Schooler, N. R., Baird, J., & Delaney, J. (1994). The prevalence of akathisia in patients receiving stable doses of clozapine. Journal of Clinical Psychiatry, 55, 142-145.
47. Chesselet, M. F., Soghomonian, J. J., & Salin, P. (1995). Anatomical localization and regulation of somatostatin gene expression in the basal ganglia and its clinical implications. Ciba Foundation Symposia, 190, 51-59.
48. Chiodo, L. A., & Bunney, B. S. (1985). Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. Journal of Neuroscience, 5, 2539-2544.
49. Chow, E. W. C., Bury, A. S., Roy, R., Basset, A. S., & Collins, E. J. (1996). The effect of clozapine on aggression [Abstract]. Abstracts of the 149th annual meeting of the American Psychiatric Association, p. 170. New York.
50. Chui, E., Burrows, G., & Stevenson, J. (1976). Double-blind comparison of clozapine in acute schizophrenic illness. Australian and New Zealand Journal of Medicine, 10, 343-347.
51. Claghorn, J., Honigfeld, G., Abuzzahab, F., Wang, R., Steinbook, R., Tuason, V., & Klerman, G. (1987). The risks and benefits of clozapine vs. chlorpromazine. Journal of Clinical Psychopharmacology, 7, 377-384.
52. Cloninger, C. R., Crow, T. J., Weisman, M. M., Fink, M., Endicott, J., Taylor, M. A., Kendler, K. S., Winokur, G., & Gershon, E. S. (1994). Is there a genetic Kraepelinian dichotomy for manic depressive illness and schizophrenia? In C. R. Cloninger & E. S. Gershon (Eds.), Genetic approaches to mental illness (pp. 149-203). New York: American Psychopathological Association.
53. Cohen, S. A., & Underwood, M. T. (1994). The use of clozapine in a mentally retarded and aggressive population. Journal of Clinical Psychiatry, 55, 440-444.
54. Cole, J. O., Banov, M. D., Green, A., & Zarate, C. A. (1993). Clozapine in the treatment of refractory acute mania [Abstract]. Abstracts of the 146th annual meeting of the American Psychiatric Association, p. 174. San Francisco, CA.
55. Cole, J. O., Gordos, G., Tarsy, D., Granacher, R. P., Sniffm, C., Vanderkolk, B., & Trenholm, I. (1980). Drug trials in persistent dyskinesia. In W. E. Fann, R. C. Smith, J. M. Davis, & E. F. Domino (Eds.), Tardive dyskinesia: Research and treatment (pp. 419-427). New York: SP Medical and Scientific Books.
56. Cole, J. O., Zarate, C. A., Banov, M. D., & Green, A. (1993). Clozapine in affective disorders [Abstract]. Proceedings of the 32nd annual meeting of the American College of Neuropsychopharmacology, p. 69. Honolulu, HI.
57. 2 dopamine receptor- mediated behaviors. European Journal of Pharmacology, 159, 141-147.
58. Dassa, D., Kaladjian, A., Azorin, J. M., & Giudicelli, S. (1993). Clozapine in the treatment of psychotic refractory depression. British Journal of Psychiatry. 163, 822-824.
59. de Leon, J., Verghese, C., Stanilla, J. K., Lawrence, T., & Simpson, G. M. (1995). Treatment of polydipsia and hyponatremia in psychiatric patients. Can clozapine be a new option? Neuropsychopharmacology, 12, 133-138.
60. Di Chiara, G., & Imperato, A. (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proceedings of the National Academy of Sciences, USA, 85, 5274-5278.
61. Dubovsky, S. L. (1993). Calcium antagonists in manic-depressive illness. Neuropsychobiology, 27, 184-192.
62. Dubovsky, S. L., Christiano, J., & Daniell, L. C. (1989a). Abnormal intracellular calcium ion concentration in platelets and lymphocytes in bipolar patients. American Journal of Psychiatry, 149, 118-120.
63. Dubovsky, S. L., Christiano, J., & Daniell, L. C. (1989b). Increased platelet intracellular calcium concentration in patients with bipolar affective disorders. Archives of General Psychiatry, 46, 632-638.
64. Dunner, D. L., & Fieve, R. R. (1974). Clinical factors in lithium carbonate prophylaxis failure. Archives of General Psychiatry, 30, 229-233.
65. Dupont, E., Hansen, H. J., & Dalby, M. A. (1973). Treatment of benign essential tremor with propranolol. Acta Neurologica Scandinavica, 49, 75-84.
66. Essock, S. M., Hargreaves, W. A., Dohm, F-A., Goethe, J., Carver, L., & Hipshman, L. (1996). Clozapine eligibility among state hospital patients. Schizophrenia Bulletin, 22, 15-25.
67. Factor, S. A., & Brown, D. (1992). Clozapine prevents recurrence of psychosis in Parkinson's Disease. Movement Disorders, 7, 125-131.
68. Factor, S. A., Brown, D., Molho, E. S., & Podskalny, G. D. (1994). Clozapine: A two-year open trial in Parkinson's Disease. Neurology, 44, 544-546.
69. Factor, S. A., Molho, E. S., Podskalny, G. D., & Brown, D. (1995). Parkinson's Disease: Drug-induced psychiatric states. Advances in Neurology, 65, 115-138.
70. Fahn, S. (1972). Differential diagnosis of tremors. Medical Clinics of North America, 56, 1363-1373.
71. Farde, L., & Nordstrom, A. L. (1992). PET analysis indicates atypical central dopamine receptor occupancy in clozapinetreated patients. British Journal of Psychiatry, 160 (Suppl. 17), 30-33.
72. Findley, L., Cleeves, L., & Calzetti, S. (1986). Primidone in essential tremor of the hands and head: A double-blind controlled clinical study. Journal of Neurology, Neurosurgery and Psychiatry, 48, 911-915.
73. Fischer, P. A., Baas, H., & Hefner, R. (1990). Treatment of parkinsonian tremor with clozapine. Journal of Neural Transmission (Parkinson 's Disease and Dementia Section), 2, 233-238.
74. Fischer-Cornelssen, K. A., & Ferner, U. J. (1976). An example of European multicenter trials: Multispectral analysis of clozapine. Psychopharmacological Bulletin, 12, 34-39.
75. Fox, A. P., Hirning, L. D., & Mogul, D. J. (1991). Modulation of calcium channels by neurotransmitters, hormones and second messengers. In L. Hurwitz, L. D. Partridge, & J. K. Leach (Eds.), Calcium channels: Their properties, functions, regulation and clinical relevance (pp. 251-263). Boca Raton, FL: CRC Press.
76. Frankenburg, F. R. (1994). Experience with clozapine in refractory psychotic illnesses. In Standards of care in schizophrenia-Proceedings of a consensus conference, (pp. 3-19). East Hanover, NJ: Sandoz Pharmaceutical Corporation.
77. Frankenburg, F. R., & Zanarini, M. C. (1993). Clozapine treatment of borderline patients: A preliminary study. Comprehensive Psychiatry, 34, 402-405.
78. Frazier, J. A., Giedd, J. N., Kaysen, D., Albus, K., Hamburger, S., & Alaghband-Rad, J. (1995). Childhood-onset schizophrenia: Brain MRI rescan after 2 years of clozapine maintenance treatment. American Journal of Psychiatry, 153, 564-566.
79. Frazier, J. A., Gordon, C. T., McKenna, K., Lenane, M. C., Jih, D., & Rapoport, J. L. (1994). An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 658-663.
80. Friedman, J. H. (1994). Clozapine treatment of psychosis in patients with tardive dystonia: Report of three cases. Movement Disorders, 9, 321-324.
81. Friedman, J. H., & Lannon, M. C. (1990). Clozapine-responsive tremor in Parkinson's Disease. Movement Disorders, 5, 225-229.
82. Frye, M. A., Altschuler, L. I., & Bitrain, J. A. (1996). Clozapine in rapid cycling bipolar disorder. Journal of Clinical Psychopharmacology, 16, 87-89.
83. Gerbino, L., Shopsin, B., & Collora, M. (1980). Clozapine in the treatment of tardive dyskinesia: An interim report. In W. E. Fann, R. C. Smith, J. M. Davis, & E. F. Domino (Eds.), Tardive dyskinesia, research and treatment (pp. 419-427). New York: SP Medical and Scientific Books.
84. Gerlach, J., & Simmelsgard, H. (1978). Tardive dyskinesia during and following treatment with haloperidol and biperiden, thioridazine and clozapine. Psychopharmacology, 59, 105-112.
85. Gerlach, J., Thorsen, K., & Fog, R. (1975). Extrapyramidal reactions and amine metabolites in CSF during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia, 40, 341-350.
86. George, T. P., Sernyak, M. J., Ziedonis, D. M., & Woods, S. W. (1995). Effects of clozapine on smoking in chronic schizophrenic outpatients. Journal of Clinical Psychiatry, 56, 344-346.
87. Gerson, S. L. (1993). Clozapine: Deciphering the risks. New England Journal of Medicine, 329, 204-205.
88. Gerson, S. L. (1994). G-CSF and the management of clozapine -induced agranulocytosis. Journal of Clinical Psychiatry, 55 (Suppl. B), 139-142.
89. Gerson, S. L., Gullion, G., Yeh, H. S., & Masor, C. (1992). Granulocyte colony-stimulating factor for clozapine-induced agranulocytosis. Lancet, 340, 1097.
90. Goff, D. C., Tsai, G., Beal, M. F., & Coyle, J. T. (1995). Tardive dyskinesia and substrates of energy metabolism in the CSF. American Journal of Psychiatry, 152, 1730-1736.
91. Gordon, C. T., Frazier, J. A., McKenna, K., Giedd, J., Zametkin, A., Hommer, D., Hong, W., Kaysen, D., Albus, K. E., & Rapoport, J. L. (1994). Childhood-onset schizophrenia: An NIMH study in progress. Schizophrenia Bulletin, 20, 697-712.
92. Guirguis, E., Voineskos, G., Gray, J., & Schlieman, E. (1977). Clozapine (Leponex) vs. chlorpromazine (Largactil) in acute schizophrenia. Current Therapeutic Research, 21, 707-719.
93. Gupta, S., & Baker, P. (1994). Clozapine treatment of polydipsia. Annals of Clinical Psychiatry, 6, 135-137.
94. Guy, W. (1976a). Abnormal Involuntary Movement Scale. In W. Guy (Ed.), ECDEU assessment manual for psychopharmacol- ogy (pp. 534-537). Washington, DC: United States Government Printing Office.
95. Guy, W. (1976b). Clinical global impressions. In W. Guy (Ed.), ECDEU assessment manual for psychopharmacology (pp. 217-222). Washington, DC: United States Government Printing Office.
96. Hall, D. D., & Hellams, J. J. (1987). Treatment outcomes with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment resistant-psychosis. Journal of Clinical Psychiatry, 48, 263-267.
97. Hamner, M. B. (1996). Clozapine treatment for a veteran with comorbid psychosis and PTSD. American Journal of Psychiatry, 153, 841.
98. Henderson, D. C., & Goff, D. C. (1994). Clozapine for polydipsia and hyponatremia in chronic schizophrenics. Biological Psychiatry, 36, 768-770.
99. Herrera, J. N., Sramek, J. J., Costa, J. F., Roy, S., Heh, C. W., & Nguyen, B. N. (1988). High potency neuroleptics and violence in schizophrenics. Journal of Nervous and Mental Disorders, 176, 558-561.
100. Hippius, H. (1989). The history of clozapine. Psychopharmacology, 99, S3-S5.
101. Hirsch, S. R., & Puri, B. K. (1993). Clozapine: Progress in treating refractory schizophrenia. British Medical Journal, 306, 1427-1428.
102. Honigfeld, G. (1996). Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatric Services, 47, 52-56.
103. Honigfeld, G., Patin, J., & Singer, J. (1984). Clozapine: Antipsychotic activity in treatment-resistant schizophrenics. Advances in Therapy, 1, 77-97.
104. Hoschl, C., & Kozemy, J. ( 1989a). Verapamil in affective disorders: A controlled, double-blind study. Biological Psychiatry, 25, 128-140.
105. Hoschl, C., & Kozemy, J. (1989b). Verapamil versus lithium in acute mania. American Journal of Psychiatry, 149, 121-122.
106. Hughes, J. R., Hatsukami, D. K., Mitchell, J. E., & Dahlgren, L. A. (1986). Prevalence of smoking among psychiatric outpatients. American Journal of Psychiatry, 143, 993-997.
107. Hyman, S. E., & Nestler, E. J. ( 1994). The molecular foundations of psychiatry. Washington, DC: American Psychiatric Press.
108. Idaanpaan-Heikkila, J., Alhava, E., Olkinoua, M., & Palva, I. (1975). Clozapine and agranulocytosis. Lancet, 2, 611.
109. Jacobsen, L. K., Walker, M. C., Edwards, J. E., Chappell, P. B., & Woolston, J. L. (1994). Clozapine treatment of a young adolescent with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 645-650.
110. Jaffe, E., Tremeau, F., Sharif, Z., & Rieder, R. O. (1995). Clozapine in Tardive Tourette's syndrome. Biological Psychiatry, 38, 196-197.
111. Jahan, M. S., Farooque, A. I., & Wahid, Z. (1992). Neuroleptic malignant syndrome. Journal of the National Medical Association, 84, 966-970.
112. Jansen, E. N. H. (1994). Clozapine in the treatment of tremor in Parkinson's Disease. Acta Neurologica Scandinavica, 89, 262-265.
113. Juul Polvsen, V. J., Noring, U., Fog, R., & Gerlach, J. (1985). Tolerability and therapeutic effects of clozapine: A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatrica Scandinavica, 71, 176-185.
114. Kahn, N., Freeman, A., Juncos, J. L., Manning, D., & Watts, R. L. (1991). Clozapine is beneficial for psychosis in Parkinson's Disease. Neurology, 41, 1699-1700.
115. Kalian, M., Lerner, V., & Goldman, M. (1993). Atypical variants of tardive dyskinesia treated with a combination of clozapine with propranolol and clozapine with tetrabenzene. Journal of Nervous and Mental Diseases, 181, 649-651.
116. Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozaril Collaborative Group: Clozapine for treatment-resistant schizophrenia: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
117. Kapur, S., & Remington, G. (1996). Serotonin-dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry, 153, 466-476.
118. Kimmel, S. E., Calabrese, J. R., Woyshville, M. J., & Meltzer, H. Y. (1994). Clozapine in treatment-refractory mood disorders. Journal of Clinical Psychiatry, 55 (Suppl. B), 91-93.
119. King, R. A., & Noshpitz, J. D. (1991). Schizophrenia in childhood and adolescence, with an overview of childhood psychosis. In J. D. Noshpitz (Ed.), Pathways of growth-essentials of childhood psychiatry (pp. 96-97). New York: Wiley.
120. Kukopulous, A., Reginaldi, D., Laddomada, P., Flori, G., Serra, G., & Tondo, P. (1980). Course of the manic-depressive cycle and changes caused by treatment. Pharmacopsychiatry, 13, 156-167.
121. Lamberti, J. S., & Bellnier, T. (1993). Clozapine and tardive dystonia. Journal of Nervous and Mental Diseases, 181, 137-138.
122. Lange, E., Konig, L., Kuhne, G. E., & Liefke, T. (1975). Clinical experience with Leponex. Psychiatric Neurology and Medical Psychology, 27, 360-365.
123. Lee, H. S., Kwon, K. Y., Alphs, L. D., & Meltzer, H. Y. (1991). Effects of clozapine on psychogenic polydipsia in chronic schizophrenia. Journal of Clinical Psychopharmacology, 11, 222-223.
124. Leppig, M., Bosch, B., Naber, D., & Hippius, H. (1989a). Clinical management of clozapine patients in relation to efficacy and side-effects. British Journal of Psychiatry, 160 (Suppl. 17), 54-59.
125. Leppig, M., Bosch, B., Naber, D., & Hippius, H. (1989b). Clozapine in the treatment of 121 outpatients. Psychopharmacology, 99, S77-S79.
126. Levin, H., Chengappa, K. N., Kambhampati, R. K., Madhavi, N., & Ganguli, R. (1992). Should chronic treatment-resistant akathisia be an indication for the use of clozapine in schizophrenic patients? Journal of Clinical Psychiatry, 53, 248-251.
127. Lieberman, J. A. ( 1993). Understanding the mechanism of action of atypical antipsychotic drugs. British Journal of Psychiatry, 163, 7-18.
128. Lieberman, J. A., Johns, C. A., Cooper, T., Pollack, S., & Kane, J. M. (1989). Clozapine pharmacology and tardive dyskinesia. Psychopharmacology, 99, S54-S59.
129. Lieberman, J. A., Kane, J. M., Safferman, A. Z., Pollack, S., Howard, A., Szymanski, S., Masiar, M. D., Kronig, M. D., Cooper, T., & Novacenko, M. S. (1994). Predictors of response to clozapine. Journal of Clinical Psychiatry, 55 (Suppl. B), 126-128.
130. Lieberman, J. A., & Safferman, A. Z. (1992). Clinical profile of clozapine: Adverse reactions and agranulocytosis. Psychiatric Quarterly, 63, 51-70.
131. Lieberman, J. A., Safferman, A. Z., Pollack, S., Szymanski, S., Johns, C. A., Howard, A., Kronig, M., Bookstein, P., & Kane, J. M. (1994). Clinical effects of clozapine in chronic schizophrenia: Treatment response and predictors of outcome. American Journal of Psychiatry, 151, 1744-1752.
132. Lieberman, J. A., Saltz, B. L., Johns, C. A., Pollack, S., Borenstein, M., & Kane, J. M. (1991). The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158, 503-510.
133. Linazasoro, G., Masso, J. F. M., & Suarez, J. A. (1993). Nocturnal akathisia in Parkinson's disease: Treatment with clozapine. Movement Disorders, 8, 171-174.
134. Lindstrom, L. H. (1988). The effect of long-term treatment with clozapine in schizophrenia: A retrospective study in 96 patients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica, 71, 524-529.
135. Lindstrom, L. H. (1989). A retrospective study on the long-term efficacy of clozapine in 96 schizophrenic and schizo affective patients during a thirteen year period. Psychopharmacology, 99, S73-S76.
136. Linnoila, M., Virkkunen, M., Scheinin, M., Nuutila, A., Rimon, R., & Goodwin, F. K. (1983). Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sciences, 33, 2609-2614.
137. Longhurst, J. G. (1995). Neuroleptic malignant syndrome. British Journal of Psychiatry, 166, 537-538.
138. Loscher, W., & Honnack, D. (1993). Effects of the competitive NMDA receptor antagonist CGP 37849 on anticonvulsant activity and adverse effects of valproate in amygdala-kindled rats. European Journal of Pharmacology, 234, 237-245.
139. Maier, G. J. (1992). The impact of clozapine on 25 forensic patients. Bulletin of the American Academy of Psychiatry and Law, 20, 297-307.
140. Mallya, A. R., Roos, P. D., & Roebuck-Colgan, K. (1992). Restraint, seclusion and clozapine. Journal of Clinical Psychiatry, 53, 395-397.
141. Marcus, P., & Snyder, R. (1995). Reduction of comorbid substance abuse with clozapine. American Journal of Psychiatry, 152, 959.
142. Marder, S. R., & Van Putten, T. (1988). Who should receive clozapine? Archives of General Psychiatry, 45, 865-867.
143. Mayer, M. L., Benveniste, M., Patneau, D. K., & Vyklicky, L. J. (1992). Pharmacologic properties of NMDA receptors. Annals of the New York Academy of Science, 648, 194-204.
144. McCarthy, R. H. (1994). Clozapine reduces essential tremor independent of its antipsychotic effect: A case report. Journal of Clinical Psychopharmacology, 14, 212-213.
145. McDougle, C. J., Barr, L. C., Goodman, W. K., Pelton, G. H., Aronson, S. C., Anand, A., & Price, L. H. (1995). Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. American Journal of Psychiatry, 152, 1812-1814.
146. McElroy, S. L., Dessain, E. C., Pope, H. G., Cole, J. O., Keck, P. E., Frankenberg, F. R., Aizley, H. G., & O'Brien, S. (1991). Clozapine in the treatment of psychotic mood disorders, schizoaffective disorders and schizophrenia. Journal of Clinical Psychiatry, 52, 411-414.
147. McEvoy, J., Freudenreich, O., McGee, M., Vanderzwaag, C., Levin, E., & Rose, J. (1995). Clozapine decreases smoking in patients with chronic schizophrenia. Biological Psychiatry, 37, 550-552.
148. 2 antagonist, decreases craving for cocaine by rats. Pharmacology Biochemistry and Behavior, 46, 125-129.
149. Meltzer, H. Y. (1990a). Commentary: Defining treatment refractoriness in schizophrenia. Schizophrenia Bulletin, 16, 563-565.
150. Meltzer, H. Y. (1990b). The neuroendocrine profile of clozapine, an atypical antipsychotic agent. Journal of Clinical Psychiatry Monograph, 8, 15-21.
151. Meltzer, H. Y. (1991). The mechanism of action of novel antipsychotic drugs. Schizophrenia Bulletin, 17, 263-287.
152. Meltzer, H. Y. (1995). Atypical antipsychotic drugs. In F. E. Bloom & D. J. Kupfer (Eds.), Psychopharmacology: The fourth generation of progress (pp. 1277-1286). New York: Raven Press.
153. Meltzer, H. Y., Burnett, S., Bastani, B., & Ramirez, L. F. (1990). Effect of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 41, 892-897.
154. Meltzer, H. Y., & Cola, P. A. (1994). The pharmacoeconomics of clozapine: A review. Journal of Clinical Psychiatry, 55 (Suppl. B), 161-165.
155. Meltzer, H. Y., Cola, P. A., Way, L., Thompson, P. A., Bastani, B., Davies, M. A., & Snitz, B. (1993). Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. American Journal of Psychiatry, 150, 1630-1638.
156. Meltzer, H. Y., Kennedy, M. D., Dai, J., Parsa, M., & Riley, D. (1995). Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's Disease. Neuropsychopharmacology, 12, 39-45.
157. Michals, M. L., Crimson, M. L., Roberts, S., & Childs, A. (1993). Clozapine response and adverse effects in nine brain injured patients. Journal of Clinical Psychopharmacology, 13, 198-203.
158. 2+ homeostasis. Progress in Neurobiology, 37, 225-285.
159. Morphy, M. A., Feldman, J. A., & Kilburn, G. ( 1989). Hallervorden-Spatz disease in a psychiatric setting. Journal of Clinical Psychiatry, 50, 66-67.
160. Mozes, T., Toren, P., Chernauzean, N., Mester, R., Yoran-Hegesh, R., Blumensohn, R.,& Weizman, A. (1994). Clozapine treatment in very early onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 65-70.
161. Mueser, K. T., Yarnold, P. R., Levinson, D. F., Singh, H., Belleack, A. S., Kee, K., Morrison, R. L., & Yadalam, K. G. (1990). Prevalence of substance abuse in schizophrenia: Demographic and clinical correlates. Schizophrenia Bulletin, 16, 31-53.
162. Muller, P., & Heipertz, R. (1977). Treatment of manic psychosis with clozapine. Fortschrift der Neurologie und Psychiatrie von Grenzgebern, 45, 420-424.
163. Myers, R. D., Lankford, M., & Bjork, A. (1992). Selective reduction by the 5-HT antagonist amperozide of alcohol preference induced in rats by systematic cyanamide. Pharmacology Biochemistry and Behavior, 43, 661-667.
164. Naber, D., & Hippius, H. (1990). The European experience with the use of clozapine. Hospital and Community Psychiatry, 41, 886-890.
165. Naber, D., Holzbach, R., Perro, C., & Hippius, H. (1992). Clinical management of clozapine patients in relation to efficacy and side-effects. British Journal of Psychiatry, 160 (Suppl. 17), 54-59.
166. Naber, D., Leppig, M., Grohmann, R., & Hippius, H. (1989). Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients. Psychopharmacology, 99, S73-S76.
167. Nahuneck, E., Rodova, A., Svestka, J., Kamenicka, V., Ceskova, E., & Misureck, J. (1973). Clinical experience with clozapine in endogenous depression. Activitas Nervosa Superior, 15, 111.
168. 2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. American Journal of Psychiatry, 152, 1444-1449.
169. Overall, J. E., & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799-812.
170. Pakkenberg, H., & Pakkenberg, B. (1986). Clozapine in the treatment of tremor. Acta Neurologica Scandinavica, 73, 295-297.
171. Parsa, M. A., Ramirez, L. F., Loula, E. C., & Meltzer, H. Y. (1991). Effect of clozapine on psychotic depression and parkinsonism. Journal of Clinical Psychopharmacology, 11, 330-331.
172. Parsa, M. A., Simon, M., Dubrow, C., Ramirez, L. F., & Meltzer, H. Y. (1993). Psychiatric manifestations of olivo-ponto-cere- bellar atrophy and treatment with clozapine. International Journal of Psychiatry in Medicine, 23, 149-156.
173. Peltier, R. L., Emmett-Oglesby, M. W., Thomas, W. H., & Schenk, S. (1994). Failure of ritanserin to block the discriminative or reinforcing stimulus effects of cocaine. Pharmacology Biochemistry and Behavior, 48, 473-478.
174. Pickar, D. ( 1995). Prospects for pharmacotherapy of schizophrenia. Lancet, 345, 557-562.
175. Pickar, D., Owen, R. R., Litman, R. E., Hsiao, J. K., & Su, T. P. (1994). Predictors of response in schizophrenia. Journal of Clinical Psychiatry, 55, 129-132.
176. Pickar, D., Owen, R. R., Litman, R. E., Konicki, E., Gutierrez, R., & Rapoport, M. H. (1992). Clinical and biological response to clozapine in patients with schizophrenia: Crossover comparison with fluphenazine. Archives of General Psychiatry, 49, 345-353.
177. Post, R. M., Ketter, T. A., & Pazzaglia, P. J. (1993). New developments in the use of anticonvulsants as mood stabilizers. Neuropsychobiology, 27, 132-137.
178. Privitera, M. R., Lamberti, J. S., & Maharaj, K. (1993). Clozapine in a bipolar depressed patient. American Journal of Psychiatry, 150, 986.
179. Ratey, J. J., & Gordon, A. (1993). The psychopharmacology of aggression: Towards a new day. Psychopharmacological Bulletin, 29, 65-73.
180. Ratey, J. J., & Leveroni, C. (1993). The effects of clozapine on severely aggressive psychiatric inpatients in a state hospital. Journal of Clinical Psychiatry, 54, 219-223.
181. Regeur, L. (1992). Clinical evaluation and pharmacological treatment of Gilles de la Tourette's syndrome and other hyperkinesias. Acta Neurologica Scandinavica, 137, 48-50.
182. Reid, W. H., Mason, M., & Toprac, M. (1994). Savings in hospital bed days related to treatment with clozapine. Hospital and Community Psychiatry, 45, 261-264.
183. Remschmidt, H. E., Schulz, E., Martin, M., Warnke, A., & Trott, G. E.
184. Revecki, D. A., Luce, B. R., Weschler, J. M., Brown, R. E., & Adler, M. A. (1990). Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hospital and Community Psychiatry, 41, 850-854.
185. Roberts, C. S., & Vickers, G. (1984). Atypical neuroleptics increase self-administration of cocaine: An evaluation of a behavioral screen for antipsychotic activity. Psychopharmacology, 82, 135-139.
186. Rodova, A., Svestka, J., Nahuneck, E., Kamenicka, V., Ceskova, E., & Misureck, J. (1973). A blind comparison of clozapine with perphenazine in schizophrenics. Activitas Nervosa Superior, 15, 94-95.
187. Rupp, A., & Kieth, S. J. (1993). The cost of schizophrenia. Psychiatric Clinics of North America, 16, 413-423.
188. Sachs, G. S., Lafer, B., & Truman, C. J. (1994). Lithium monotherapy: Miracle, myth and misunderstanding. Psychiatric Annals, 24, 229-233.
189. Safferman, A., Lieberman, J. A., Kane, J. M., Szymanski, S., & Kinon, B. (1991). Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin, 17, 247-261.
190. Sajatovic, M., Ramirez, L. F., Kenny, J. T., & Meltzer, H. Y. (1994). The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. Comprehensive Psychiatry, 35, 29-33.
191. Sajatovic, M., Verbanac, P., Ramirez, L. F., & Meltzer, H. Y. (1991). Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in Huntington's chorea. Neurology, 41, 156.
192. Schmidt, M. H., Trott, G. E., & Nissen, G. (1990). Clozapine medication in adolescence. In C. N. Stephanis, A. D. Rabavilas, & C. R. Soldatos (Eds.), Psychiatry: A world perspective, Vol. 1, Proceedings of the VIII World Congress of Psychiatry (pp. 1100-1104). Amsterdam: Excerpta Medica.
193. Scholz, E., & Dichgans, J. (1985). Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. European Archives of Psychiatric and Neurological Sciences, 235, 60-64.
194. Schott, K., Ried, R., Stevens, I., & Dichgans, J. (1989). Neuroleptically-induced dystonia in Huntington's disease: A case report. European Neurology, 29, 39-40.
195. 2-like dopamine receptor agonists. Science, 271, 1586-1589.
196. Shopsin, B., Klein, H., Aaronsom, M., & Collora, M. (1979). Clozapine, chlorpromazine and placebo in newly hospitalized, acutely schizophrenic patients: A controlled, double-blind study. Archives of General Psychiatry, 36, 657-664.
197. Simpson, G. M., Lee, J. H., & Shrivastara, R. K. (1978). Clozapine in tardive dyskinesia. Psychopharmacology, 56, 75-80.
198. Skelton, J. A., Pepe, M. M., & Pineo, T. S. (1995). How much better is clozapine? A meta-analytic review and critical appraisal. Experimental and Clinical Psychopharmacology, 3, 270-279.
199. Small, J. G., Milstein, V., Marhenke, J. D., Hall, D. D., & Hellams, J. J. (1987). Treatment outcomes with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment-resistant psychosis. Journal of Clinical Psychiatry, 48, 263-267.
200. Spears, N. M., Leadbetter, R. A., & Shutty, M. S. (1996). Clozapine treatment in polydipsia and intermittent hyponatremia. Journal of Clinical Psychiatry, 57, 123-128.
201. Stoudemire, A., & Clayton, L. (1989). Successful use of clozapine in a patient with a history of neuroleptic malignant syndrome. Journal of Neuropsychiatry and Clinical Neuroscience, 1, 303-305.
202. Suppes, T., McElroy, S. L., Gilbert, J., Dessain, E. C., & Cole, J. O. (1992). Clozapine in the treatment of dysphoric mania. Biological Psychiatry, 32, 270-280.
203. Susman, E. (1996). Clozapine looks promising for childhood schizophrenia. Psychopharmacology Update, 7, 1-3.
204. Tamminga, C. A., Thaker, G. K., Moran, M., Kakigi, T., & Gao, X.-M. (1994). Clozapine in tardive dyskinesia: Observations from human and animal model studies. Journal of Clinical Psychiatry, 55 (Suppl. B), 102-106.
205. Thiel, A., Dressler, D., Kistel, C., & Ruther, E. (1994). Clozapine treatment of spastic torticollis. Neurology, 44, 957-958.
206. Towbin, K. E., Dykens, E. M., & Pugliese, R. G. (1994). Clozapine for early developmental delays with childhood-onset schizophrenia: Protocol and 15-month outcome. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 651-657.
207. Trugman, J. M., Leadbetter, R., Zalis, M. E., Burgdorf, R. O., & Woolen, G. F. (1994). Treatment of severe axial tardive dystonia with clozapine: Case report and hypothesis. Movement Disorders, 9, 441-446.
208. Tsai, G., Crisostomo, G., Rosenblatt, M. L., & Stern, T. A. (1995). Neuroleptic malignant syndrome associated with clozapine treatment. Annals of Clinical Psychiatry, 7, 91-95.
209. Tsuang, M. T. (1979). Schizoaffective disorder. Archives of General Psychiatry, 36, 633-634.
210. Uehlinger, C., & Baumann, P. (1991). Clozapine as an alternative treatment for neuroleptic induced gynecomastia. American Journal of Psychiatry, 148, 392-393.
211. Van Praag, H. M., Korf, J., & Dois, L. C. W. (1976). Clozapine versus perphenazine: The value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity. British Journal of Psychiatry, 129, 547-555.
212. Van Putten, T. (1974). Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry, 31, 67-72.
213. Van Putten, T., May, P. R. A., & Marder, S. R. (1984). Akathisia with haloperidol and thiothixine. Archives of General Psychiatry, 41, 1036-1039.
214. Van Putten, T., Mutalipassi, L. R., & Malkin, M. D. (1974). Phenothiazine-induced decompensation. Archives of Central Psychiatry, 30, 102-105.
215. Van Putten, T., Wirshing, W. C., & Marder, S. R. (1990). Tardive Meige syndrome responsive to clozapine. Journal of Clinical Psychopharmacology, 10, 381-382.
216. 4 receptor with high affinity for the antipsychotic clozapine. Nature, 350, 610-614.
217. Volavka, J., Zito, J. M., Vitrai, J., & Czobor, P. (1993). Clozapine effects on hostility and aggression in schizophrenia. Journal of Clinical Psychopharmacology, 13, 287-289.
218. Vyncke, J. (1974). The treatment of behavior disorders in idiocy and imbecility with clozapine. Pharmacopsychiatry, 7, 225-229.
219. Werry, J. S. (1992). Child and adolescent (early onset) schizophrenia: A review in the light of DSM-III-R. Journal of Autism and Developmental Disorders, 22, 601-624.
220. Winokur, G., Monahan, P., Coryell, W., & Zimmerman, M. (1996). Schizophrenia and affective disorder-distinct entities or continuum?: An analysis based on a prospective 6-year follow-up. Comprehensive Psychiatry, 37, 77-87.
221. Wolf, M. E., & Mosnaim, A. D. (1994). Improvement of axial dystonia with the administration of clozapine. International Journal of Clinical Pharmacology and Therapeutics, 32, 282-283.
222. Wolters, E. C., Hurwitz, T. A., Mak, E., Teal, P., Peppard, F. R., Remick, R., Calne, S., & Calne, D. B. (1990). Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology, 40, 832-834.
223. Wood, M. J., & Rubenstein, M. (1990). An atypical responder to clozapine. American Journal of Psychiatry, 147, 369.
224. Young, C. R., Bostic, J. Q., & McDanald, C. L. (1994). Clozapine and refractory obsessive-compulsive disorder: A case report. Journal of Clinical Psychopharmacology, 14, 209-210.
225. Young, C. R., Bowers, M. B., & Mazure, C. M. (in press). Management of the adverse effects of clozapine. Schizophrenia Bulletin.
226. Yovell, Y., & Opler, L. A. (1994). Clozapine reverses cocaine craving in a treatment-resistant mentally ill chemical abuser: A case report and a hypothesis. Journal of Nervous and Mental Disorders, 182, 591-592.
227. Zarate, C. A., Tohen, M., Banov, M. D., Weiss, M. K., & Cole, J. O. (1995). Is clozapine a mood stabilizer? Journal of Clinical Psychiatry, 56, 108-112.
228. Zhang, M., Owen, R. R., Pope, S. K., & Smith, G. R. (1996). Cost-effectiveness of clozapine monitoring after the first six months. Archives of General Psychiatry, 53, 954-959.
229. Zito, J. M., Volvka, J., Craig, T. J., Czobar, P., Banks, S., & Vitrai, J. (1993). Pharmacoepidemiology of clozapine in 202 inpatients with schizophrenia. Pharmacoepidemiology, 27, 1262-1269.
230. Zuddas, A., Ledda, M. G., Fratta, A., Muglia, P., & Cianchetti, C. (1996). Clinical effects of clozapine in autistic disorder. American Journal of Psychiatry, 153, 738.